Key result
Drug-eluting stents provide a viable alternative to coronary artery bypass grafting for diabetic patients with multivessel coronary disease, dramatically reducing restenosis rates compared to older percutaneous techniques.
Why the study?
Is percutaneous coronary intervention with drug-eluting stents a viable alternative to coronary artery bypass grafting for revascularization in diabetic patients?
Is percutaneous coronary intervention with drug-eluting stents a viable alternative to coronary artery bypass grafting for revascularization in diabetic patients?
With the advent of drug-eluting stents and optimal adjunctive pharmacology, percutaneous coronary intervention has become a viable, minimally invasive alternative to CABG for diabetic patients with multivessel coronary artery disease.
Answers are grounded in this paper and cite their sources.
May support DES-PCI consideration in diabetic multivessel disease; leaves open need for contemporary RCTs versus CABG.
The field of interventional cardiology has progressed rapidly in recent years with the advent of new technology and expanding role of adjunctive pharmacology. This article provides an overview of both current and historical approaches to treating coronary artery disease in the diabetic patient.
No takes yet. Share an insight, caveat, or question.
Butts et al. (2006) conducted a review in Coronary artery disease in diabetic patients. Percutaneous coronary intervention (drug-eluting stents) vs. Coronary artery bypass grafting (CABG) was evaluated. Drug-eluting stents provide a viable alternative to coronary artery bypass grafting for diabetic patients with multivessel coronary disease, dramatically reducing restenosis rates compared to older percutaneous techniques.
Synapse has enriched 10 related papers. Consider them for comparative context: